CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $353,976 | +532.1% | 56,276 | +232.9% | 0.00% | – |
| Q4 2021 | $56,000 | -13.8% | 16,904 | -0.0% | 0.00% | – |
| Q3 2021 | $65,000 | +54.8% | 16,906 | +73.2% | 0.00% | – |
| Q1 2021 | $42,000 | -65.3% | 9,759 | -47.3% | 0.00% | – |
| Q4 2020 | $121,000 | +51.2% | 18,530 | +68.1% | 0.00% | – |
| Q3 2020 | $80,000 | +81.8% | 11,020 | -17.2% | 0.00% | – |
| Q2 2020 | $44,000 | +2100.0% | 13,309 | +698.4% | 0.00% | – |
| Q1 2020 | $2,000 | -88.2% | 1,667 | -80.9% | 0.00% | – |
| Q4 2019 | $17,000 | -94.6% | 8,747 | -85.6% | 0.00% | – |
| Q3 2019 | $312,000 | +550.0% | 60,877 | +799.1% | 0.00% | – |
| Q2 2019 | $48,000 | +700.0% | 6,771 | +1372.0% | 0.00% | – |
| Q1 2019 | $6,000 | -14.3% | 460 | -44.4% | 0.00% | – |
| Q4 2018 | $7,000 | 0.0% | 828 | +38.9% | 0.00% | – |
| Q3 2018 | $7,000 | +16.7% | 596 | +42.6% | 0.00% | – |
| Q2 2018 | $6,000 | – | 418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |